Sat, Jul 26, 2014, 7:21 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

PolyMedix, Inc. Message Board

mulletman99 13 posts  |  Last Activity: Jul 2, 2014 2:11 PM Member since: Feb 1, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • OH THE HYPOCRISY!!!!!!
    Where was the right's outrage over Bush not only getting a National Guard position b/c he was too much of a pu$$eeee to go to war, but then deserted his Natl Guard?

    "Try him and then hang him".....right board bagger????!!!!

    LMFAO!!!!

    I love seeing you still here, wasting your life away. Its better you are here instead of spreading your hate and idiocy in the real world. LMFAO!

    Hey Jack!!!

  • Its official, there are MORE jobs now than at the peak prior to Bush destroying the economy. And Obama did this inspite of the GOP meeting in a backroom on inauguration day and agreeing to try to stop him from doing anything, and a record number of fillibusters.

  • mulletman99 mulletman99 Jun 6, 2014 11:21 AM Flag

    Yup. The right is SOOOOOOO upset that this guy apparently, speculatively, maybe abandoned his post. Yet, they didnt seem to care that Bush wasnt even man enough to go, and on top of that, DID, ABSOLUTELY, WITH 100% CERTAINTY, ABANDONED HIS POST at the Natl Guard.

    OH THE HYPOCRISY!!!!!

  • Reply to

    New 8K filed for product licensing

    by onebarkmill Jul 2, 2014 11:23 AM
    mulletman99 mulletman99 Jul 2, 2014 11:50 AM Flag

    Key sentence:
    The Agreements were entered into primarily for the purpose of separating the Company's rights and obligations with respect to its different product development programs.

    My guess has always been.....they will partner off BFPET and use the money to fund CardioPET and go that alone. We will see, but it looks like this was a necessary step for financing of some sort.

  • Reply to

    Once Market Volatility Begins

    by investron Jun 11, 2014 10:46 PM
    mulletman99 mulletman99 Jun 12, 2014 11:02 AM Flag

    Once again Investron, your rhetoric does not jive with reality.

    Check the 6 month chart of ARWR vs TKMR. Over the last 6 months they have been hand-in-hand, so whatever (TECHNICALLY - CHART AND PPS WISE) you have to say about TKMR OBVIOUSLY applies to ARWR as well, based on the last 6 months of chart history.

    You must be VERY VERY bored with your life to spend so much time on the message board of a stock you dont even own. Get outside.....its nice out. Go hang with your family if you have one.....Im sure they arent THAT bad.

  • FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO

    8:34 AM ET 5/29/14 | Marketwire

    FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue 18F-FCPHA will be presented by the principal investigator, Olivier Gheysens, MD, PhD, at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

    The study was conducted at the University Hospital Leuven, Belgium. Collaborators on this study include Olivier Gheysens, MD, PhD, Andrey Postnov, PhD, Johan Nuyts, PhD, Koen Van Laere, MD, PhD, DrSc (Department of Nuclear Medicine & Molecular Imaging, University Hospital Leuven, Belgium), Stefan Janssens, MD, PhD (Department of Cardiology, University Hospital Leuven, Belgium) and Manuel Cerqueira, MD (Department of Nuclear Medicine, Cleveland Clinic, Cleveland, Ohio USA.)

  • mulletman99 mulletman99 Jun 11, 2014 1:47 PM Flag

    The 1st post cut off the rest of the article, so here it is:

    Also.....after looking at the data posted by Zach's, it is obvious to me that "may be feasible" isnt anything to worry about. This data is WOW data, IMO.

    The compilation of the clinical data continues to reinforce our belief that CardioPET has potential to unseat the current standard imaging agents for coronary artery disease imaging.

    We cover FPMI with an Outperform rating and $2.15/share price target. See below for access to our most recent report on the company.

  • http://lifetechcapital.com/ltc/2014/06/fluoropharma-fpmi-update-06-03-14/

  • 06/11/2014
    By Brian Marckx, CFA

    OBB:FMPI

    Quantitative Phase II Data Provides Additional Support of CardioPET Utility

    FluoroPharma Inc. (OBB:FPMI) presented additional data from its ongoing phase II study of CardioPet during this week's Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) in St. Louis.

    As a reminder, CardioPET is being developed as a PET imaging agent to better diagnose acute and chronic coronary artery disease (CAD), among other potential indications. The Belgian-based phase II trial is an open label study designed to assess safety and performance of CardioPET compared to SPECT myocardial perfusion imaging (MPI) agents and angiography.

    In February of this year, at the SNMMI mid-Winter meeting held in Pam Springs, FPMI presented data on fifteen patients that demonstrated CardioPET enters the myocardium similar to the way of fatty acids, remains there long enough to allow for PET imaging but with rapid clearance, thereby minimizing patient exposure to imaging radiation. Image quality was considered excellent as was safety. The data indicated that CardioPET has the ability to attain high quality images very shortly after injection.

    The data presented this week at SNMMI in St. Louis reinforced the findings of the earlier data and provided a quantitative output of results. The quantitative output is presented in graphical form, showing both the rapid uptake and clearance (chart left) of CardioPET as well as how CardioPET can differentiate between normal and damaged tissue (chart right). While the excellent quality of CardioPET images provides a reliable qualitative measure for physicians in diagnosing CAD, this quantitative output demonstrated with the current data provides what is essentially a double-check of the images, offering physicians another tool with CardioPET PET imaging.

    ​ The compilation of the clinical data continues to reinforce our belief that CardioPET has potential to unseat the current standard ima

  • http://interactive.snm.org/index.cfm?PageID=13072&A=11&B=106&E=667&PID=66757

  • Reply to

    Data presented June 10th - Tuesday - 2:45pm

    by mulletman99 Jun 9, 2014 11:09 AM
    mulletman99 mulletman99 Jun 10, 2014 10:50 AM Flag

    Yes. they released preliminary data back in February and the resolution looked fantastic compared to the current standard. No safety issues either. See write-ups by LifeTech or Zachs, or 1 of theIr presentations for the pictures and info presented. The BRIley presentation was the best, IMO.

  • Reply to

    New 8K filed for product licensing

    by onebarkmill Jul 2, 2014 11:23 AM
    mulletman99 mulletman99 Jul 2, 2014 2:11 PM Flag

    Higher revenue potential for BFPET (according to the company) but CardioPET further along in development, so I'm not sure the market would care either way. Although the difference between the 2 wrt revenue projections is very small, while time to market could be significantly sooner for CardioPET.....hence my preference to partner out BFPET and get a revenue stream sooner.

  • This was NOT the full phase 2 results.....THATS why the stock response is what it is.

    From their phase 2 design description:
    Secondary Objective:
    A secondary objective is to assess fatty acid uptake at rest and following stress.

    Check out the abstract for this presentation. It was for 5 people, 2 at rest and 3 after stress test.

    The phase 2 study has 30-40 patients total.....not 5.

    IMO, These results were very good.. Hospitals, doctors and insurance companies all like data driven decisions. This showed that they could quantify (put a number to or get data from) the blood flow into the heart tissue (perfusion) to help drive decisions on how to treat. This in combination with the higher resolution images shown in the interim analysis given in Feb point to a high market penetration if this is eventually approved.

    All IMO........think for yourselves.

PYMXQ
0.020.00(0.00%)Jul 25 8:10 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.